Self-Reported Exercise Tolerance and the Risk of Serious Perioperative Complications

Total Page:16

File Type:pdf, Size:1020Kb

Load more

ORIGINAL INVESTIGATION Self-reported Exercise Tolerance and the Risk of Serious Perioperative Complications Dominic F. Reilly, MD; Marguerite J. McNeely, MD, MPH; Diane Doerner, MD, PhD; Deborah L. Greenberg, MD; Thomas O. Staiger, MD; Michael J. Geist, MD; Philip A. Vedovatti, MD; John E. Coffey, MD; Marc W. Mora, MD; Timothy R. Johnson, MD; Eugenia D. Guray, MD; Gail A. Van Norman, MD; Stephan D. Fihn, MD, MPH Background: Impaired exercise tolerance during for- Results: Patients reporting poor exercise tolerance had mal testing is predictive of perioperative complications. more perioperative complications (20.4% vs 10.4%; However, for most patients, formal exercise testing is not P,.001). Specifically, they had more myocardial ische- indicated, and exercise tolerance is assessed by history. mia (P = .02) and more cardiovascular (P = .04) and neu- rologic (P = .03) events. Poor exercise tolerance pre- Objective: To determine the relationship between self- dicted risk for serious complications independent of all reported exercise tolerance and serious perioperative com- other patient characteristics, including age (adjusted odds plications. ratio, 1.94; 95% confidence interval, 1.19-3.17). The like- lihood of a serious complication occurring was inversely Methods: Our study group consisted of 600 consecu- related to the number blocks that could be walked tive outpatients referred to a medical consultation clinic (P= .006) or flights of stairs that could be climbed (P = .01). at a tertiary care medical center for preoperative evalu- Other patient characteristics predicting serious compli- ation before undergoing 612 major noncardiac proce- cations in multivariable regression analysis included his- dures. Patients were asked to estimate the number of tory of congestive heart failure, dementia, Parkinson dis- blocks they could walk and flights of stairs they could ease, and smoking greater than or equal to 20 pack-years. climb without experiencing symptomatic limitation. Pa- tients who could not walk 4 blocks and climb 2 flights Conclusion: Self-reported exercise tolerance can be used of stairs were considered to have poor exercise toler- to predict in-hospital perioperative risk, even when us- ance. All patients were evaluated for the development of ing relatively simple and familiar measures. 26 serious complications that occurred during hospital- ization. Arch Intern Med. 1999;159:2185-2192 ISK ASSESSMENT is an impor- tive complications.12-17 McPhail et al13 tant component of the pre- showed that among patients undergoing operative evaluation. It is vascular surgery, those with a good per- used in planning periop- formance during treadmill testing or arm erative treatment1 and to ergometry had fewer postoperative car- help shape decisions about the advisabil- diovascular complications. In addition, R 2 12,17 ity and extent of surgery. Factors consid- Gerson et al showed that geriatric pa- ered in assessing an individual’s risk for tients who were unable to exercise for 2 surgery include the nature of the proce- minutes with supine bicycle ergometry had dure to be performed and the severity of more cardiovascular and pulmonary com- comorbid medical problems. Prolonged plications. Other studies, in highly se- procedures3-5 and those with significant lected populations, have also shown that physiologic stress3,6,7 (eg, thoracic sur- patients who perform poorly on standard- gery) are associated with increased risk. ized testing have a worse prognosis after From the Division of General The presence and severity of medical ill- surgery.14-16 Internal Medicine (Drs Reilly, ness correlate with an increased risk for Unfortunately, formal exercise test- McNeely, Doerner, Greenberg, perioperative complications,6-11 espe- ing is expensive, time-consuming, and not Staiger, Geist, Vedovatti, cially in the setting of emergent surgery.7 specifically indicated for most patients. As Coffey, Mora, Johnson, Guray, and Fihn) and the Department Exercise tolerance may be another im- a result, clinicians usually determine a pa- of Anesthesiology portant factor to consider when assess- tient’s exercise tolerance from the pa- 1,2 (Dr Van Norman), University ing a patient’s surgical risk. Patients with tient’s history. Patients are asked to de- of Washington Medical Center, poor exercise tolerance on formal testing scribe the nature and frequency of their Seattle. have been shown to have more periopera- physical activities. This is then considered ARCH INTERN MED/ VOL 159, OCT 11, 1999 WWW.ARCHINTERNMED.COM 2185 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 PATIENTS AND METHODS We asked each patient to estimate the number of blocks they could walk (0-4) on level ground and the number of flights of stairs (0-4) they could climb without experienc- The study was conducted at the University of Washington ing symptomatic limitation. We chose these measures for Medical Center, Seattle, a 450-bed academic medical cen- their simplicity and familiarity to the average clinician (they ter providing tertiary surgical and medical care to the resi- are similar to the Canadian classification system used for dents of the northwestern United States. All outpatients aged quantifying the severity of angina6). Limiting symptoms were 18 years and older referred to the medical consulting ser- recorded when available. Complete exercise tolerance in- vice clinic for preoperative consultation prior to noncar- formation was unavailable for 4 patients. These patients were diac surgery from October 17,1995, through June 9,1997, conservatively classified as having poor exercise tolerance were eligible to participate. All participants provided writ- for the purposes of analysis. There was a higher rate of com- ten informed consent. The study was approved by our in- plications in the group with poor exercise tolerance when stitutional review committee. these 4 patients were excluded from analysis. A atient was considered to have a medical problem if PATIENTS 2 or more of the following criteria were satisfied: history consistent with the diagnosis, supportive physical find- Patients were referred to the clinic by the surgical team or ings, positive diagnostic test results, or treatment for the by anesthetists when they had concerns about the pa- illness. Patients were classified as having ventricular ar- tient’s medical problems. Approximately 15% of patients rhythmias when they had more than 5 premature ventricu- undergoing surgery at the University of Washington are re- lar contractions per minute.7 The diagnosis of obstructive ferred to the clinic for preoperative evaluation. Of the 951 lung disease included patients with either emphysema or consecutive patients referred to the clinic during the study asthma. A patient’s age was calculated as of the day of period, 896 (94%) consented to participate. Of these, 229 surgery. Goldman7 and Detsky6 scores were calculated (26%) were undergoing a minor procedure and were ex- for all patients, using previously published definitions cluded. Minor procedures, defined as those with mini- (Appendix 1 and Appendix 2). mum risk for serious complications,6 included biopsy, cen- If a patient’s surgical procedure was directly related tral venous catheter placement, lumpectomy without node to the treatment or diagnosis of a possible malignant neo- dissection, transurethral resection of the prostate or blad- plasm, it was considered to be oncology related. The Ameri- der tumor, inguinal hernia repairs, and all ophthalmo- can Society of Anesthesiologists (ASA) classification11,19 was logic procedures except enucleation. assigned by the attending anesthesiologist on the day of sur- Of the 667 patients having major procedures, 67 (10%) gery (Table 1). Anesthesia data were obtained from the had their procedures canceled, leaving 600 patients to form Department of Anesthesia’s existing quality improvement our study group. Procedures were considered to be can- database or the anesthesia record. The length of stay was celed if not scheduled at the University of Washington Medi- calculated from the date of surgery until discharge. Length cal Center within 90 days of the evaluation. Twelve pa- of stay data for 3 patients admitted to the physiatry ward tients underwent 2 procedures, each with a distinct directly after surgery were excluded. Their long hospital admission and discharge. To be as inclusive as possible, all stays (25, 88, and 99 days) were planned in advance and analyses were based on 612 procedures. Reanalysis using reflected, in large part, their need for other services. only 1 procedure per patient (n = 600) while randomly ex- cluding 12 procedures resulted in no appreciable change PERIOPERATIVE COMPLICATIONS in the results. A list of perioperative complications and their definitions DATA COLLECTION was composed before the study was started (Table 2). Five major categories of complications were established: Each patient provided an extensive history and under- cardiovascular, pulmonary, neurologic, infectious, and went a thorough physical examination. These evaluations miscellaneous. We also recorded deaths, unexpected were conducted by an attending internist or a senior medi- transfers to the intensive care unit (ICU) or cardiac telem- cal resident. Outside records were sought and preopera- etry ward, and activation of the medical center’s emer- tive testing was ordered as clinically indicated. No addi- gency response system (code blue). Other complications tional testing
Recommended publications
  • Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
  • Free PDF Download

    Free PDF Download

    European Review for Medical and Pharmacological Sciences 2012; 16: 1611-1636 The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina A. DI MONACO, A. SESTITO Department of Cardiology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy Abstract. – Ischemic heart disease (IHD) is a serve is exhausted2. Symptom severity can be major cause of death in Western Countries and modulated by dynamic vasomotion at the site of accounts for very high costs worldwide. In this re- stenoses and/or by coronary microvascular dys- view we discussed the pathogenesis, symptoms, 1,2 diagnosis, prognosis and management of chronic function . IHD. In particular, we discussed about the percu- In microvascular angina transient myocardial taneous coronary interventions and coronary ischemia is caused by coronary microvascular artery bypass grafting, as well as to clinical trials dysfunction in patients with angiographically that evaluated the advantages of one approach normal epicardial coronary arteries, in the ab- versus another. Pharmacological treatment is 3,4 among major objectives of the review and for sence of any other specific cardiac disease . In each class of therapeutic agents an evaluation of vasospastic angina transient myocardial is- well-conducted clinical trials is provided. The chemia is caused by coronary spasm5. most important drug classes in IHD treatment are Furthermore, angina and transient myocardial betablockers, calcium channel blockers, nitrates, ischemia may also occur in patients with non ath- antiplatelet agents, and ACE-inhibitors. In addition to these agents, also new treatment options are erosclerotic obstructive coronary artery disease, evaluated in patients with stable IHD.
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al

    (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al

    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.
  • Calcium Channel Blockers in Cardiovascular Pharmacotherapy

    Calcium Channel Blockers in Cardiovascular Pharmacotherapy

    Cardiovascular Pharmacology Core Review Journal of Cardiovascular Pharmacology and Therapeutics 2014, Vol. 19(6) 501-515 Calcium Channel Blockers in ª The Author(s) 2014 Reprints and permission: Cardiovascular Pharmacotherapy sagepub.com/journalsPermissions.nav DOI: 10.1177/1074248414530508 cpt.sagepub.com Theophile Godfraind1 Abstract This paper summarizes the pharmacological properties of calcium channel blockers (CCBs), their established therapeutic uses for cardiovascular disorders and the current improvement of their clinical effects through drug combinations. Their identification resulted from study of small molecules including coronary dilators, which were named calcium antagonists. Further experiments showed that they reduced contraction of arteries by inhibiting calcium entry and by interacting with binding sites identified on voltage-dependent calcium channels. This led to the denomination calcium channel blockers. In short-term studies, by decreasing total peripheral resistance, CCBs lower arterial pressure. By unloading the heart and increasing coronary blood flow, CCBs improve myocardial oxygenation. In long-term treatment, the decrease in blood pressure is more pronounced in hypertensive than in normotensive patients. A controversy on the safety of CCBs ended after a large antihypertensive trial (ALLHAT) sponsored by the National Heart, Lung, and Blood Institute. There are two main types of CCBs: dihydopyridine and non-dihydropyridine; the first type is vascular selective. Dihydropyrines are indicated for hypertension, chronic, stable and vasospastic angina. Non-dihydropyridines have the same indications plus antiarrythmic effects in atrial fibrillation or flutter and paroxysmal supraventricular tachycardia. In addition, CCBs reduced newly formed coronary lesions in atherosclerosis. In order to reach recommended blood pressure goals, there is a recent therapeutic move by combination of CCBs with other antihypertensive agents particularly with inhibitors acting at the level of the renin-angiotensin system.
  • Medcompgx Med List

    Medcompgx Med List

    For more info, go to: MedCompGx.com Medications Conditions / Uses Other Uses CYP2C19 Anticonvulsants Lacosamide (Vimpat) Epilepsy, Seizures Phenobarbital (Luminal) Epilepsy, Seizures Barbituates, Anxiety, Sedation, Withdrawl Primidone (Mysoline) Epilepsy, Seizures Zonisamide (Zonegran) Epilepsy, Seizures Antifungals Voriconazole (Vfend) Yeast Infections, Candidiasis, Aspergillosis, Candida, Aspergillus Antidepressants Escitalopram (Lexapro) SSRI, Depression, Anxiety Citalopram (Celexa) SSRI, Depression, Anxiety OCD Sertraline (Zoloft) SSRI, Depression, Anxiety OCD, PTSD Doxepin (Silenor) Tricyclic Antidepressant, Depression Bipolar, Insomnia Imipramine (Tofranil) Tricyclic Antidepressant, Depression Trimipramine (Surmontil) Tricyclic Antidepressant, Depression Amitriptyline (Elavil) Tricyclic Antidepressant, Depression Clomipramine (Anafranil) Tricyclic Antidepressant, Depression OCD Benzodiazepines Clobazam (Onfi) Seizures Diazepam (Valium) Seizures, Muscle Spasms, Anxiety, Alcohol Withdrawl Beta Blockers Labetalol (Normodyne, Trandate) High Blood Pressure, Hypertension Immunomodulators Leflunomide (Arava) Rheumatoid Arthritis Tofacitinib (Xeljanz) Rheumatoid Arthritis Muscle Relaxants Carisoprodol (Soma) Muscle Pain, Muscle Spasms Opioids Meperidine (Demerol) Pain, Severe Pain, Narcotic, Opiate Proton Pump Inhibitors Dexlansoprazole (Dexilant) GERD, Acid Reflux, Gastric Esophageal Reflux, Ulcers, Heartburn, Zollinger-Ellison Syndrome Esomeprazole (Nexium) GERD, Acid Reflux, Gastric Esophageal Reflux, Ulcers, Heartburn, Zollinger-Ellison
  • World Health Organization Model List of Essential Medicines, 21St List, 2019

    World Health Organization Model List of Essential Medicines, 21St List, 2019

    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
  • Ukrainian Medical Stomatological Academy

    Ukrainian Medical Stomatological Academy

    Poltava State Medical University Department of Experimental and Clinical Pharmacology Lecture 9 Module 1 MEDICINAL DRUGS INFLUENCING CARDIO-VASCULAR SYSTEM. MEDICINAL DRUGS FOR TREATMENT OF ISCHEMIC HEART DISEASE. HYPOLIPIDEMIC DRUGS. ANGIOPROTECTORS Prepared by Ye.Vazhnichaya [email protected], +380666347273 CONTENTS A. Antianginal drugs 1. Pathogenesis of angina pectoris and ways to its control 2. Classification of the antianginal grugs 3. Drugs that decrease oxygen demand and increase oxygen supply 4. Drugs decreasing oxygen demand of the myocardium 5. Drugs increasing oxygen supply to the myocardium 6. Drugs increasing the myocardium stability to hypoxia B. Antiatherosclerotic drugs 1. Pathogenesis of aherosclerosis and its management 2. Classification of the antiatherosclerotic drugs 3. Hypolipidemic agents 4. Antioxidants 5. Antiplatelets 6. Angioprotectors C. Control tasks ANTIANGINAL DRUGS ISCHEMIC HEART DISEASE Ischemic heart disease Angina Myocardial Myocardial pectoris infarction sclerosis ANGINA PECTORIS Angina pectoris is characterized by a sudden, severe pressing or acute chest pain radiating to the left arm and neck. Anginal pain occurs when the oxygen supply to myocardium is insufficient for its needs. The imbalance between oxygen delivery and utilization may result from a spasm or from obstruction of heart blood vessels. The coronary blood flow is insufficient to meet the heart’s metabolic requirements. It causes the onset of anginal pain. MAIN CAUSES OF ANGINA ATTACK: thrombosis, atherosclerosis and spasm of coronary blood vessels ANTIANGINAL DRUGS: pharmacological management Pharmacological management in angina pectoris includes: Decrease in oxygen demand of myocardium Increase in oxygen supply Changes of myocardium metabolism in favor of stability to oxygen insufficiency. ANTIANGINAL DRUGS: classification A. Drugs that decrease oxygen demand of myocardium and increase oxygen supply 1.
  • Child and Adolescent Psychopharmacology Manual

    Child and Adolescent Psychopharmacology Manual

    Southern Consortium for Children Athens, Hocking, Vinton 317 Board ADAMHS Board of Adams-Lawrence-Scioto Counties Gallia-Jackson-Meigs Board of ADAMHS Washington County MHAR Board CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY MANUAL Issued: November 2005 Compiled by: Peg Meis, M.Ed., LPCC, Director of Crisis Services Reviewed by: Edward Lynam, M.D. & Linda Adams, R.N., MSN Designed by: Jenny Metts Preface To the User: This manual has been put together for informational purposes only. It is not meant to be used for clinical practice. Each physician will have their own methodology in treating children and adolescents, as many of these drugs have not been fully tested for use with patients under the age of 18. It is strongly advised that when questions arise regarding medication for a specific youth that those questions be referred to the treating physician. • Please be aware and attuned to the possible side effects of any medication, especially at the onset of starting any new medication. • In particular, suicidal ideation with antidepressants, stimulants, and Strattera. • Watch for adverse effects of all stimulants, such as hallucinations and psychosis. It is our hope that this manual will be helpful in the field for therapists, case managers, counselors, court personnel, and child-serving agencies. We encourage you to reproduce this manual as needed and to distribute it to all staff who may benefit from its use. This manual can also be downloaded online by going to www.scchildren.com. Southern Consortium for Children Post Office Box 956 Athens, Ohio 45701 740-593-8293 Phone / 740-592-4170 Fax Contact: Peg Meis [email protected] www.scchildren.com Table of Contents ADHD Treatment Adderal.............................................................................................................
  • Polypharmacy Guidance 2015 and Work with a Team That Are Committed to Improving Outcomes for Patients

    Polypharmacy Guidance 2015 and Work with a Team That Are Committed to Improving Outcomes for Patients

    Acknowledgements It has been a pleasure to chair the development of this Polypharmacy Guidance 2015 and work with a team that are committed to improving outcomes for patients. This document has been produced by the collaborative efforts of the clinicians from multidisciplinary backgrounds that make up the Model of Care Group from across Scotland. They are already delivering on polypharmacy reviews to improve appropriate prescribing and patient safety. In addition the Data, Indicators and Evaluation Group have provided the tools and data to help target patients. There has also been the development of national indicators that are available for boards to use at practice level for peer review and improvement. We have been supported by a team of Medicines information Pharmacists from across Scotland under the leadership of Janice Watt and Melinda Cuthbert who have worked to provide the data to support the numbers needed to treat (NNT) tables, and are listed below. Finally I would like to thank Tobias Dreischulte, Simon Hurding and Jason Cormack for the support that they have provided in terms of the structure and presentation of the document, making it far more user friendly. We are also currently working with colleagues in NES to produce a mobile app for clinicians to use when undertaking the reviews. Model of Care Group Alpana Mair, Deputy Chief Pharmaceutical Officer, Scottish Government (Chair) Martin Wilson, Consultant, NHS Highland Miles Witham, Consultant, NHS Tayside Graeme McPhee, Consultant, NHS Greater Glasgow and Clyde Kathryn
  • Triptolol Is Once a Day at Bedtime

    Triptolol Is Once a Day at Bedtime

    1. Generic Name Amitriptyline Hydrochloride + Propranolol Hydrochloride 2. Qualitative and Quantitative Composition Amitriptyline Hydrochloride IP 10mg Propranolol Hydrochloride IP 40mg 3. Dosage form and strength Oral tablets are available in the strength of Amitriptyline 10mg, Propranolol 40mg 4. Clinical particulars 4.1 Therapeutic indication Migraine with co-morbid conditions like Insomnia, Neuralgic Pain, Hypertension, Anxiety 4.2 Posology and method of administration Recommended oral dose of Triptolol is once a day at bedtime. 4.3 Contraindication The use of Triptolol Tablet is contraindicated in patients with: • Known hypersensitivity to any ingredient in this product. • On prescription of MAO inhibiting compound. • Severe hepatic dysfunction. • history of urinary retention – BPH • cardiogenic Shock, sinus Bradycardia and greater than first degree block, bronchial Asthma 4.4 Special warnings and precautions for use • Triptolol Tablet should be used with caution in patients with renal or hepatic dysfunction and cardiovascular problems. • Caution is advised in untreated angle-closure glaucoma, phaeochromocytoma, and hyperthyroidism. • Avoid consuming alcohol when taking the Triptolol as it may cause excessive drowsiness. 4.5 Drug interactions • Amitriptyline Most common (but not the only) medications used that have the potential for major drug interactions when combined with amitriptyline are duloxetine, citalopram, fluoxetine, topiramate, tramadol, sertraline, cyclobenzaprine and trazodone Most common (but not the only) medications
  • Pharmacology

    Pharmacology

    STATE ESTABLISHMENT «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE» V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV, A.E. LIEVYKH, E.V.KHOMIAK PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT DNEPROPETROVSK - 2016 2 UDC: 378.180.6:61:615(075.5) Pharmacology. Workbook for practical classes for foreign stomatology students / V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov. - Dnepropetrovsk, 2016. – 186 p. Reviewed by: N.I. Voloshchuk - MD, Professor of Pharmacology "Vinnitsa N.I. Pirogov National Medical University.‖ L.V. Savchenkova – Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology, State Establishment ―Lugansk state medical university‖ E.A. Podpletnyaya – Doctor of Pharmacy, Professor, Head of the Department of General and Clinical Pharmacy, State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ Approved and recommended for publication by the CMC of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ (protocol №3 from 25.12.2012). The educational tutorial contains materials for practical classes and final module control on Pharmacology. The tutorial was prepared to improve self-learning of Pharmacology and optimization of practical classes. It contains questions for self-study for practical classes and final module control, prescription tasks, pharmacological terms that students must know in a particular topic, medical forms of main drugs, multiple choice questions (tests) for self- control, basic and additional references. This tutorial is also a student workbook that provides the entire scope of student’s work during Pharmacology course according to the credit-modular system. The tutorial was drawn up in accordance with the working program on Pharmacology approved by CMC of SE ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ on the basis of the standard program on Pharmacology for stomatology students of III - IV levels of accreditation in the specialties Stomatology – 7.110105, Kiev 2011.
  • Generics Only Preventive Therapy Drug List

    Generics Only Preventive Therapy Drug List

    High Deductible Health Plan (HDHP) - Health Savings Account (HSA) Generics Only Preventive Therapy Drug List (09/01/20) ANTICOAGULANTS/ sotalol AF pioglitazone/glimepiride Pacerone pioglitazone/metformin ANTIPLATELETS repaglinide ANTICOAGULANTS ORAL ANTIANGINAL AGENTS tolbutamide enoxaparin isosorbide dinitrate fondaparinux isosorbide mononitrate HYPERTENSION warfarin isosorbide mononitrate ext-rel Jantoven ACE INHIBITORS/ANGIOTENSIN II RECEPTOR ANTAGONISTS AND COMBINATION AGENTS SL and chewable formulations are not included amlodipine/benazepril PLATELET AGGREGATION INHIBITORS on this list. aspirin 81 mg benazepril clopidogrel TRANSDERMAL/TOPICAL ANTIANGINAL benazepril/hydrochlorothiazide dipyridamole AGENTS candesartan dipyridamole ext-rel/aspirin nitroglycerin transdermal candesartan/hydrochlorothiazide prasugrel Minitran captopril captopril/hydrochlorothiazide Over-the-Counter (OTC) products require a prescription. CORONARY ARTERY DISEASE enalapril Coverage may vary by plan. enalapril/hydrochlorothiazide ANTIHYPERLIPIDEMICS fosinopril atorvastatin fosinopril/hydrochlorothiazide ANTICONVULSANTS cholestyramine carbamazepine irbesartan colesevelam irbesartan/hydrochlorothiazide carbamazepine ext-rel colestipol clobazam lisinopril ezetimibe lisinopril/hydrochlorothiazide clonazepam fenofibrate divalproex sodium delayed-rel losartan fenofibric acid delayed-rel losartan/hydrochlorothiazide divalproex sodium ext-rel fluvastatin ethosuximide moexipril fluvastatin ext-rel olmesartan felbamate gemfibrozil lamotrigine olmesartan/hydrochlorothiazide